PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction no persons are required to respond to a collection of information unless it contains a valid OMB Complete if Known

Substitute for form 1449B/PTO INFORMATION STATEMENT B

(use as many shee

Sheet

<i>1</i> 0TO					
/PTO	CCI	OCUDE	Application Number	10/815,388	
	_	OSURE	Filing Date	March 31, 2004	
BY APPLICANT eets as necessary)			First Named Inventor	Pablo Caviedes	
			Group Art Unit	1651	
sets as necessary)		essary)	Examiner Name	Allison M. Ford	
	of	4	Attorney Docket Number	USF-167XC1	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. '	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²			
ag	ALLEN, D.D. et el. "Impaired cholinergic function in cell lines derived from the cerebral cortex of normal and trisomy 16 mice" Eur. J. Neurosci., 2000, 12:3259-3264.					
az	R2	ALLEN, D.D. et al. "A dorsal root ganglia cell line derived from trisomy 16 fetal mice, a model for Down syndrome" NeuroReport, 2002, 13:491-496.				
0	R3	ANDREWS, B.A. et al. "Factors for the Optimization of the Culture of Neuronal Cell Lines for the Development of Cell Transplant Material" poster presented at the Cell Culture & Engineering Conference in Snowmass, CO, April 1-6, 2002.				
00	R4	ARRIAGADA, C. et al. "Studies of aminochrome toxicity in a mouse derived neuronal cell line: is this toxicity mediated via glutamate transmission?" Amino Acids, 2000, 18:363-373.				
0	R5	BARROS, V.G. et al. "Corticosterone down-regulates dopamine D ₄ receptor in a mouse cerebral cortex neuronal cell line" Neurotoxicity Res., 2003, 5(5):369-374.				
as	R6	BHADRIRAJU, K. and HANSEN, L.K. "Hepatocyte adhesion, growth and differentiated function on RGD-containing proteins" <i>Biomaterials</i> , 2000, 21:267-272.	·			
az	R7	CÁRDENAS, A. et al. "Cell lines derived from hippocampal neurons of the normal and trisomy 16 mouse fetus (a model for down syndrome) exhibit neuronal markers, cholinergic function, and functional neurotransmitter receptors" Experimental Neurology, 2002, 177:159-170.				
az	R8	CÁRDENAS, A. et al. "Establishment and characterization of immortalized neuronal cell lines derived from the spinal cord of normal and trisomy 16 fetal mice, an animal model of Down syndrome" J. Neurosci. Res., 2002, 68:46-58.				
95	R9	CÁRDENAS, A.M. et al. "Calcium signals in cell lines derived from the cerebral cortex of normal and trisomy 16 mice" NeuroReport., 1999, 10:363-369.				
3	` R10	CARMONA, M.T. and CAVIEDES, R. "Effects of factors derived from a tumor clonal cell line on DNA synthesis of transformed and non transformed cells" Cell Biol Int Rep., 1985, 9(3):209-218.				
2	 R11	CAVIEDES, P. et al. "Calcium fluxes, ion currents and dihydropyridine receptors in a new immortal cell line from rat heart muscle" J. Mol. Cell Cardiol., 1993, 25:829-845.				
8	R12	CAVIEDES, R. and STANBURY, J.B. "Studies on a cell line from a functional rat thyroid tumor in continuous culture" <i>Endocrinology</i> , 1976, 99:549-554.				
3	R13	CAVIEDES, R. et al. "Tetrodotoxin-sensitive sodium channels in a continuously cultured cell line derived from the adult rat cerebellum" Brain Res., 1986, 365(2):259-268.				

Examiner		Date	1115 1 2005
Signature	all of	Considered	17 Jupt. 2003
EVALUED.	tritical if reference considered whether drawed citation	on is in conformance with MPEP 609. Draw line th	rough citation if not in conformance

*EXAMINER: Initial if reference considered, whether of the chief not on conformance with MPEP 809. Draw line through charps in not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. 80x 1459, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

USF-167XC1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

	C	omplete if Known	
Substitute for form 1449B/PTO	Application Number	10/815,388	
INFORMATION DISCLOSURE	Filing Date	March 31, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Pablo Caviedes	•
(use as many sheets as necessary)	Group Art Unit	1651	
(use as many sneets as necessary)	Examiner Name	Allison M. Ford	

Attorney Docket Number

of

Sheet

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
07	R14	CAVIEDES, R. et al. "Identification of kallikrein in cultures of adult renal cells" Cell Biol Int Rep, 1987, 11(10):735-743.					
2	R15	CAVIEDES, R. et al. "Ion channels in a skeletal muscle cell line from a Duchenne muscular dystrophy patient" Muscle Nerve, 1994, 17(9):1021-1028.					
00	R16	CHEN, G. et al. "Photoimmobilization of sulfated hyaluronic acid for antithrombogenicity" Bioconj. Chem., 1997, 8:730-734.					
az	R17	CHIU, D.T. et al. "Patterned deposition of cells and proteins onto surfaces by using three-dimensional microfluidic systems" Proc. Acad. Sci. USA, 2000, 97:2408-2413.					
00	R18	CLÉMENCE, J.F. et al. *Photoimmobilization of a bioactive laminin fragment and pattern-guided selective neuronal cell attachment* Bioconjug. Chem., 1995, 6:411-417.					
az	R19	DELAMARCHE, E. et al. "Patterned diversity of immunoglobulins to surfaces using microfluidic networks" Science, 1997, 276:779-781.					
as	R20	EAGLE, H. et al. "Myo-inositol as an essential growth factor for normal and malignant human cells in tissue culture" J. Biol. Chem., 1956, 123:845-847.					
ag	R21	EAGLE, H. "Media for Animal Cell Culture" Tissue Culture Association Manual, 1976, 3:517-519.					
ag	R22	EAGLE, H. "Amino acid metabolism in mammalian cell cultures" Science, 1959, 130:432-437.					
3	R23	EAGLE, H. "Nutrition needs of mammalian cells in tissue culture" Science, 1955, 122:501-504.					
az	R24	FOLCH, A. and TONER, M. "Cellular micropatterns on biocompatible materials" <i>Biotechnol. Prog.</i> , 1998, 14:338-392.					
a	R25	HORACEK, M.J. et al. "Adult adenohypophysial cells express β, Integrins and prefer laminin during cell-substratum adhesion" In Vitro Cell. Dev. Biol., 1994, 30A:35-40.					
ax	R26	LERNHARDT, W. and SPEAR, D. "Improved adherent mammalian cell transfection with ProNectin™ F recombinant attachment factor" Strategies in Molecular Biology, 1993, 5:48-50.					

Examiner Signature	allin "	XC		Date Considered	14 Sept. 2005
*EXAMINER: Initial i	f reference considered, whether	of not	citation is in conformance with MPEP 60	9. Draw line th	rough citation if not in conformance

and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

				Con	nplete if Known
	te for form 1449B/PTC		COUDE	Application Number	10/815,388
	RMATION D			Filing Date	March 31, 2004
STAT	TEMENT BY	APP	LICANT	First Named Inventor	Pablo Caviedes
fu.	se as many sheets	20 20	occond	Group Art Unit	1651
Į D.	se as many sneets	as nec	essary)	Examiner Name	Allison M. Ford
Sheet	3	of	4	Attorney Docket Number	USF-167XC1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
00	LIBERONA, J.L. et al. "Expression of ion channels during differentiation of a human skeletal muscle cell line" J. Muscle Res. Cell Motility, 1997, 18:587-598.		
as	R28	LIBERONA, J.L. et al. "Differences in both inositol 1,4,5-trisphosphate mass and inositol 1,4,5-trisphosphate receptors between normal and dystrophic skeletal muscle cell lines" Muscle & Nerve, 1998, 21:902-909.	
or.	R29	LIU, V.A. et al. "Engineering protein and cell adhesivity using PEO-terminated triblock polymers" J. Biomed. Mater. Res., 2002, 60:126-134.	
ay	R30	LOM, B. et al. "A versatile technique for patterning biomolecules onto glass coverslips" J. Neurosci. Methods, 1993, 50:385-397.	
az	R31	.LWEBUGA-MUKASA, J.S. "A Mn ^{2*} -enhanced, RGD-dependent adhesion technique for isolation of adult rat type II alveolar epithelial cells for immediate functional studies" <i>Am. J. Respir. Cell Mol. Biol.</i> , 1994, 10:347-354.	
as	R32	MAUNG, K. et al. "Requirement for focal adhesion kinase in tumor cell adhesion" Oncogene, 1999, 18:6824-6828.	
as	R33	.NEEDELS, D.L. et al. "Long-term support by injured brain extract of a subpopulation of ciliary ganglion neurons purified by differential adhesion" Neurochem. Res., 1987, 12(10):901-907.	
az	R34	PARIS, I. et al. "Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line" J. Neurochem., 2001, 77:519-529.	
as	R35	RUOSLAHTI E. and PIERSCHBACHER, M.D. "New perspectives in cell adhesion: RGD and integrins" Science, 1987, 238:491-497.	
az	R36	SALAZAR, J. et al. "Intrastriatal implantation of RCSN adult rat substantia nigra-derived cells reverts rotational behaviour in 6OH dopamine lesioned rats" Abstract No. 300.8, Society for Neuroscience, Washington, D.C., 2003	
00	R37	SINGHVI, R. et al. "Engineering cell shape and function" Science, 1994, 264:696-698.	
α_{λ}	R38	STEDRONSKY, E.R. et al. "Injection molding of ProNectin® dispersed in polystyrene for the fabrication of plastic ware activated towards attachment of mammalian cells" Materials Research Society Symposium Proceedings, 1994, 330:157-164.	
00	R39	VARANI, J. et al. "Use of recombinant and synthetic peptides as attachment factors for cells on microcarriers" Cytotechnology, 1993, 13:89-98.	

Examiner Signature	allin &	Date Considered 14 Sept 20	05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

•				Con	nplete if Known
	te for form 1449B/PTO	601	OCUDE	Application Number	10/815,388
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	March 31, 2004
STA	LEMENT BA	APF	PLICANT	First Named Inventor	Pablo Caviedes
(use as many sheets as necessary)				Group Art Unit	1651
(use as many should as housessary)			-assary)	Examiner Name	Allison M. Ford
Sheet	4	of	4	Attorney Docket Number	USF-167XC1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city end/or country where published.	T²
$\alpha 0$	R40	ZHENG, J. et al. "Measurements of growth cone adhesion to culture surfaces by micromanipulation" J. Cell Biol., 1994, 127(6, Part 2):2049-2060.	
	R	-	
	R	·	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
-	R		
	R R		

Examiner	Allina S	P	Date	4 Sept. 2005
Signature	UUUVII)		Considered I.	7 0 7

*EXAMINER: Initial if reference considered, whether of not orditation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.